Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/3/2025

Oral Minoxidil Safety in Von Willebrand Disease

Bleeding Risk Assessment

  • Aspirin should be used with extreme caution or avoided in VWD patients with acquired von Willebrand syndrome (AvWS) who have increased bleeding risk 1

  • In patients with extreme thrombocytosis (platelet count >1 million/μL), AvWS must be ruled out with ristocetin cofactor and multimer analysis before starting any medication that could affect hemostasis 2

  • If extreme thrombocytosis persists and is accompanied by AvWS or bleeding events, aspirin and other antiplatelet agents should be avoided 2

  • Patients with VWD type 1 who have mild bleeding history and normal VWF activity levels (>50 IU/dL) can generally tolerate medications with cardiovascular effects 3

Laboratory Testing and Monitoring

  • Never assume VWD type without recent laboratory confirmation, as bleeding phenotype can change over time, particularly with development of AvWS 6, 1

  • Do not combine oral minoxidil with antiplatelet therapy in patients with platelet counts >1 million/μL without first excluding AvWS 2

  • Cardiovascular monitoring alone is insufficient - hemostatic parameters require concurrent assessment 7, 3